Percutaneous Coronary Intervention

PCIs performed on in-stent restenosis lesions are often treated with another stent, researchers found.

The landmark TAILOR-PCI trial showed encouraging evidence for genotype-guided antiplatelet therapy.

Ticagrelor (Brilinta, AstraZeneca) vs. prasugrel (Effient, Daiichi Sankyo/Eli Lilly) on clinical outcomes in patients with ACS undergoing a planned invasive strategy.

Updating current appropriate use criteria for PCI in patients with stable ischemic heart disease to include findings from the ISCHEMIA trial may reclassify a significant number of PCIs to rarely appropriate, researchers found.

At 1 year after PCI, patients with insulin-treated diabetes experienced greater risk for MACE compared with patients with no diabetes, researchers reported.

Among patients who underwent PCI, an LDL level of 70 mg/dL or more was associated with elevated risk for subsequent CV events, according to data published in the Journal of the American College of Cardiology.

Women with early-onset MI had fewer recurrent major CV events during long-term follow-up compared with men, despite sex differences regarding disease burden and preventive treatments, researchers found.

Among patients who underwent PCI for ACS and then had dual antiplatelet therapy with aspirin and prasugrel, halving the prasugrel dose after 1 month conferred reduced risk for net adverse clinical events, researchers reported.

A higher dose of a glycoprotein VI inhibitor in patients with CAD who underwent PCI resulted in more pronounced platelet inhibition without increasing bleeding risk, researchers found in the ISAR PLASTER trial.

Among patients with atrial fibrillation who underwent PCI, dual therapy with edoxaban showed similar safety and efficacy as triple therapy with a vitamin K antagonist at 1 year, regardless of whether coronary disease was acute or chronic.